SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla - Quaterly Results

13 May 2025 Evaluate
The Revenue for the quarter ended  March 2025 of Rs. 47978.90 millions grew by 18.86 % from Rs. 40366.60 millions.Profit for the quarter ended March 2025 rises by 51.26% to Rs. 14854.00  millions from Rs. 9820.30 millions.Operating profit surged to 16120.80 millions from the corresponding previous quarter of 13665.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 47978.90 40366.60 18.86 190448.50 165743.40 14.91 190448.50 165743.40 14.91
Other Income 2933.70 5386.10 -45.53 9847.20 10706.60 -8.03 9847.20 10706.60 -8.03
PBIDT 16120.80 13665.00 17.97 67631.60 55548.10 21.75 67631.60 55548.10 21.75
Interest 34.90 54.50 -35.96 151.10 202.50 -25.38 151.10 202.50 -25.38
PBDT 19032.50 13610.50 39.84 70427.10 55345.60 27.25 70427.10 55345.60 27.25
Depreciation 1477.00 1368.10 7.96 5738.90 5875.90 -2.33 5738.90 5875.90 -2.33
PBT 17555.50 12242.40 43.40 64688.20 49469.70 30.76 64688.20 49469.70 30.76
TAX 2701.50 2422.10 11.54 13111.70 12327.80 6.36 13111.70 12327.80 6.36
Deferred Tax -625.60 20.30 -3181.77 -491.50 60.90 -907.06 -491.50 60.90 -907.06
PAT 14854.00 9820.30 51.26 51576.50 37141.90 38.86 51576.50 37141.90 38.86
Equity 1615.20 1614.70 0.03 1615.20 1614.70 0.03 1615.20 1614.70 0.03
PBIDTM(%) 33.60 33.85 -0.75 35.51 33.51 5.96 35.51 33.51 5.96

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×